suggesting that this transcription factor fusion gene may promote the expression of MDR-1. We therefore tested this hypothesis directly by expressing the RUNX1-RUNX1T1 fusion as a single abnormality in human haematopoietic cell subsets and performed Affymetrix microarray analysis (as described previously) 2, 7 to determine whether this fusion had any effect on the transcription of MDR genes. Using this approach, we generated independent replicate sets of data from control and RUNX1-RUNX1T1-matched CD34 þ cultures as well as matched sets constituting granulocytic (CD14 lo , CD36 lo , CD15 hi ) and monocytic (CD14 hi ) unilineage populations (isolated from day 6 cultures by immunomagnetic sorting). cRNA was prepared from each sample and hybridized to Affymetrix human 133A oligonucleotide arrays, which allowed the simultaneous analysis of six MDR family gene members. In each of these populations, the expression of MDR genes was not significantly different from controls (Figure 1a-c) . In addition, using our cohort of FrenchAmerican-British (FAB)-M2 patients, there was little difference in MDR gene expression between those individuals with a t(8;21) and those without this abnormality ( Figure 1d ). We could therefore find no evidence that RUNX1-RUNX1T1 expression directly influences MDR gene expression as a single abnormality or in t(8;21) patients. One alternative explanation for the aforementioned observations in AML patients is that other coexisting abnormalities may be influencing the expression of MDR, as suggested by Schaich et al. 6 We next addressed the issue of whether the t(8;21) abnormality directly influences the susceptibility to chemotherapeutic agents. We therefore assessed the sensitivity of normal human cells (expressing RUNX1-RUNX1T1 as a single abnormality) to a number of drugs commonly used to treat AML (Daunorubicin, Cytarabine, Fludarabine, Idarubicin or Etoposide) in comparison with matched controls. Remarkably, none of these agents differentially affected the growth of RUNX1-RUNX1T1-transduced cells (Figure 2a-e) . As treatment of AML commonly involves multiple drugs, we also determined the effect of combining two or more of these chemotherapeutic agents (using drug concentrations that resulted in 50% reduction in cell growth as a single agent). Again, we observed little difference in the in vitro growth response of RUNX1-RUNX1T1-expressing cells compared to controls (Figure 2f ).
Taken together, these data suggest that expression of RUNX1-RUNX1T1 itself has no effect on the intrinsic susceptibility to cytotoxic chemicals. This raises the alternative hypothesis that RUNX1-RUNX1T1 moderates the influence of secondary abnormalities, which are required for RUNX1-RUNX1T1-expressing cells to undergo leukaemic transformation. 8 For example, it is known that RUNX1-RUNX1T1 specifically upregulates the expression of g-catenin in RUNX1-RUNX1T1-expressing cells and t(8;21) patients, 7,9 a protein that acts as a tumour suppressor gene in other contexts. Abbreviation: DS, discriminating score; rRNA, ribosomal RNA.
Letters to the Editor
(theoretical number of produced false positives ¼ 1.7) (Figure 1a and b), representing 228 genes and eight ESTs, of which 188 were upregulated and 48 downregulated in activated kinaseexpressing cells (Supplementary Tables 2 and 3) . To translate the RNA expression profiles into functionality, discriminator genes/ESTs were interrogated by Onto-Express. Table 1 represents the most significant (P-value inferior at 3 Â 10 À2 ) and most often represented (including at least three genes) biological processes. Many of the upregulated genes encode nucleolar proteins involved in 'ribosome biogenesis' (GO:0007046; six genes, P ¼ 4.28 Â 10 À11 ), 'rRNA processing' (GO:0006364; seven genes, P ¼ 3.07 Â 10
À11
) and 'protein biosynthesis' (GO:0006412; nine genes, P ¼ 3.60 Â 10 À05 ). Upregulated genes encode nucleolar proteins (CIRH1A, LARP1, NOL1, NOL11, NOL5, NOL5A, NOLA1, NOLA2, NOLC1, MKI67IP, SFRS2, SURF6), 3 ribosomal proteins (RPL3, RPL12, RPL41, RPS9, RRS1), small nuclear ribonucleoproteins and interactors (U3/MPHOSPH10, LSM2, RNU22, RNU3IP2), components of RNA polymerase I (POLR1A, POLR1B), II (POLR2H, TAF9) and III (POLR3E, POLR3H), DEAD-box (DDX18, DDX56) and WD repeat (WDR4, WDR43, WDR74, WDR77, GRWD1, PWP1) proteins, eucaryotic initiation and elongation factors (EIF1A, EIF3S1, EIF3S4, EEF1E1), and components of the exosome (EXOSC1, EXOSC2, EXOSC6). Upregulated genes also encode proteins of the NOL5A-associated pre-ribosomal ribonucleoprotein complex involved in pre-rRNA processing (NOL5A, PPAN, NOLC1 and BXDC2). The gene encoding EBNA1BP2 was upregulated; it encodes a protein that binds to nucleolar FGF3 4 and is regularly upregulated in tumors. The most upregulated sequence was GAS5, a non-protein-coding multiple small nucleolar RNA.
Other significant processes included 'protein folding' (GO: 0006457; four genes, P ¼ 6.72 Â 10
À03
), 'ubiquitin-dependent protein catabolism' (GO:0006511; three genes, P ¼ 1.47 Â 10
À02
), 'nuclear mRNA splicing, via spliceosome' (GO:0000398; three genes, P ¼ 1.65 Â 10
) and 'regulation of cell cycle' (GO: 0000074; three genes, P ¼ 1.65 Â 10
). The second major category of upregulated genes encodes CCND2 (cyclin D2) and CDC25A, two major regulators needed for G1 progression. CCND2 RNA was found upregulated by BCR-ABL in previous gene expression studies. [5] [6] [7] Cyclin D2 is necessary for BCR-ABLinduced activity. 7 Inhibition of V617F JAK2 correlates with decreased expression of cyclin D2. 8 Other G1 cyclins may play a role in the oncogenic activity of fusion kinases, but cyclin D2 seems to be a rate-limiting element. We used Western blot analysis to validate the differential expression of cyclin D2. The amount of cyclin D2 protein was increased in Ba/F3 cells expressing activated kinases as compared to controls (Figure 1c ), in agreement with mRNA expression results.
MYC directly or indirectly regulates the G1 phase of the cell cycle. The list of upregulated genes included MYC. Many genes upregulated by MYC and NMYC oncogenes were also upregulated in our experiments, including CCND2, CDC25A and others (DDX18, EBNA1BP2, EEF1E1, MAT2A, MKI67IP, NOL5A, NOLA1, PHB, SFRS2, SHMT1, SLC16A1, SURF6, SRM, RPL3, RPL12, RPL41, RPS9 and RRS1). 9 This similarity suggests that MYC proteins and MPD kinases have similar oncogenic effects, whose main target would be the CDKN2-RB protein pathway during the G1 phase of the cell cycle. Once induced, MYC may in turn act on the transcription of G1/S regulators and genes involved in protein synthesis. MPD fusion kinases are thought to target the hematopoietic stem cell. Activation of MYC is in perfect agreement with what we know of stem cell proliferation. A similar program was also turned on by IL-3 stimulation (not shown).
Downregulated genes were more difficult to classify with Onto-Express, but several encode proteins with known or potential inhibitory function such as protein inhibitor of activated STAT3 (PIAS3), an inhibitor of signal transducer and activator of transcription 3 (STAT3), one of the main substrates of MPD kinases, and regulator of CDC25A, 10 Erbin and PLZF/ ZBTB16, a MYC repressor. 11 We tested the validity of our classification by the 'leave-oneout' cross-validation method. Iteratively, one of the 15 samples was removed, and a multigene predictor was generated from the remaining samples: 93% of samples were correctly assigned by the predictors with a sensitivity of 89% and a specificity of 100%.
Thus, in Ba/F3 cells, MPD fusion kinases induce both G1 activators and protein synthesis components, thus starting the cell proliferation machinery. This effect may be mediated by the PI3 kinase (PI3K)-AKT-TOR pathway, which controls and coordinates both protein synthesis and early phases of the cell cycle. Prominent downstream targets of the AKT pathway are cyclins D1, D2 and MYC. 12 These conclusions have to be confirmed by repeating the experiments in other cell lines and by profiling samples of various human MPDs. This work has two general implications. First, it may help define the initial steps of oncogenesis. Cell quiescence may be defined by the absence of protein synthesis, whereas proliferation starts with nucleolar activity, ribosome biogenesis and rRNA processing. Second, MPDs could benefit from treatment targeting not only the activated kinases but also the PI3K-AKT-TOR signalling pathway and the G1 phase of the cell cycle, in synergy with anti-kinase drugs and/or in case of resistance. G1 targeting is frequent in many types of cancer. The signature defined here can be used in transcriptome studies of any type of cancer to identify G1 activation, classify tumors and use the appropriate drugs.
